The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with at least two of the following characteristics: age ≥80 years body weight ≤60 kg serum creatinine ≥1.5 mg/dL Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery The recommended dose of ELIQUIS is 2.5 mg taken … See more If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily … See more Switching from ELIQUIS to warfarin: ELIQUIS affects INR, so that initial INR measurements during the transition to warfarin may not be useful for determining the appropriate dose … See more ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. … See more For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose by 50% when ELIQUIS is coadministered with drugs that are strong dual inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) … See more WebWeight ≤60 kg Serum creatinine ≥1.5 mg/dL Hepatic impairment Mild: No dosage adjustment required Moderate: Patients may have intrinsic coagulation abnormalities; …

Eliquis Dosage Guide - Drugs.com

WebDose: 2.5 mg PO bid x35 days; Start: 12-24h postop [knee replacement] Dose: 2.5 mg PO bid x12 days; Start: 12-24h postop DVT/PE prophylaxis, recurrent [2.5 mg PO bid] WebJun 2, 2024 · For NVAF, apixaban is dosed at 5 mg orally twice daily and is reduced to 2.5 mg twice daily in patients who meet 2 of the following criteria: age > 80 years, body weight 1.5 mg/dL. 1 Placement of these criteria within the Cockcroft-Gault formula would provide an estimated glomerular filtration rate (eGFR) of approximately 30 mL/min. … screenshot significato

Apixaban - Thrombosis Canada

WebOct 1, 2024 · Decrease dose to 2.5 mg twice per day if two of the following: age 80 years or older, body weight ≤ 60 kg (132 lb); serum creatinine ≥ 1.5 mg per dL (114 μmol per L) … WebMar 7, 2024 · ELIQUIS ( apixaban ), a factor Xa (FXa) inhibitor, is chemically described as 1- (4-methoxyphenyl)-7-oxo-6- [4- (2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo [3,4c]pyridine-3-carboxamide. Its molecular formula is C 25 H 25 N 5 O 4, which corresponds to a molecular weight of 459.5. Apixaban has the following structural formula: WebDec 2, 2016 · A recent analysis of clinical trials data by the ISTH suggests that while data is limited, the available data suggests that DOACs are safe in patients less than 120 kg at … paws 2 purrfection